Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2014 / Articles / Nov / All a Big Game?
Manufacture Business Practice Technology and Equipment Trends & Forecasts Facilities & Equipment Technology & Manufacturing

All a Big Game?

“Welcome to Big Pharma, where you can make a fortune and still maintain a healthy conscience. Or can you?”

By Stephanie Vine 11/06/2014 0 min read

Share

A new video game – Big Pharma – will apparently make its debut in 2015. The teaser is somewhat satirical: “What if you had it in your power to rid the world of disease, to improve the lives of millions, to ease suffering and cure the sick… and earn a tidy profit? As the head of your own Pharmaceutical Conglomerate you have this power resting in your hands. Will you use it for good? Being totally altruistic may not be the best business plan […] some remedies are more profitable than others and illness is good for business.”

0214-201-upfront-main1

Is the game just an elaborate attempt to demonize the industry? Designer Tim Wicksteed says that isn’t the case. “Some people are incredibly damning about the pharmaceutical industry, but then others are very grateful because a medicine has saved their life. I’m trying to stay neutral and represent both standpoints. I want the player to make up their own mind about how they build their pharmaceutical business, including the ethical challenges that go with that.” Gameplay is reminiscent of the ‘Tycoon’ series of business simulation games. In Big Pharma, activities include exploring exotic locations for new ingredients and purchasing machines that can synthesize those ingredients into drug products. Players will have to compete against other companies, who may develop generic drugs at lower prices, and there will also be regulatory bodies and patents to deal with.

0214-201-upfront-main2

Wicksteed isn’t intending for the game to be an entirely accurate representation of the industry and admits that drug synthesis is completely made up, for example. “It’s a little bit cartoony with wacky, over-the-top machines. It’s a game first and foremost, so it has to be fun to play,” he explains. One area that he is keen to portray realistically is the marketplace of drug development. “I find it interesting that pharmaceutical companies have to align the goals of running a profitable drug company with making people healthy. As an example, there would be huge demand for something like an HIV vaccine, but many patients would be in developing nations and unable to pay hundreds of dollars for it. That kind of thing will be represented in the game and will give players a few things to think about. Do you make an HIV vaccine or something that panders to a richer Western market, like anti-wrinkle cream?”

Players will be under intense pressure if they want to progress and make enough money to unlock new machines, and Wicksteed hopes that it will give people food for thought. “People have asked whether it’ll be possible to sell a drug with a side effect that increases demand for another one of their products. But that might be taking the cynicism one step too far!” says Wicksteed. “There will be ‘bad things’ you can do – but there will always be consequences to those actions…”

Would you play Big Pharma? Drop us a line at charlotte.barker@texerepublishing.com or tweet @medicine_maker.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.